Arcutis Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARQT | RCUS | IOVA | 688177.SS | ZBIO | ALMS | |
|---|---|---|---|---|---|---|
| Market cap | 4.28B | 2.43B | 3.94B | 7.38B | 1.85B | 847.80M |
| P/E (TTM) | 154.8 | — | — | — | — | — |
| Forward P/E | 25.4 | -6.2 | -44.4 | -26.2 | -6.1 | -2.3 |
| Price/book | 22.2 | 3.8 | 5.4 | 171.3 | 7.3 | 1.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +35.66% | −1.28% | +276.62% | −34.43% | −12.32% | +38.77% |
| Today | +6.41% | +2.12% | −1.47% | +2.95% | +0.28% | +0.77% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARQT news ›Arcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Misses Expectations By $0.12 EPS
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12), FiscalAI reports. The business…
Arcutis Biotherapeutics, Inc. Announces Appointment of Rob Scott as Director and Member of Nominating and Corporate Governance Committee, Effective October 23, 2026
Arcutis Biotherapeutics, Inc. announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Robert Scott also appointed as Nominating and Corporate... announced that Rob Scott, MD has…
Chronic Hand Eczema Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics
Albany New York November 03 2026 As per DelveInsight s assessment globally Chronic Hand Eczema pipeline constitutes 5 key companies continuously working towards developing 5 Chronic Hand Eczema treatment therapies analysis of Clinical…
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, openPR.com Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis…
Arcutis Biotherapeutics (ARQT) Set to Release Quarterly Earnings on Wednesday
Posted by Mitch Edgeman on Nov 2nd, 2026 Get Our Latest Stock Report on ARQT Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The…
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Has Average Target Price of $38.00
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have…
Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and $48 price target ... Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald…
Arcutis Biotherapeutics presents data across Zoryve portfolio
Arcutis Biotherapeutics (ARQT) announced data presented across its Zoryve portfolio as well as real-world research on the long-term use of topic... Arcutis Biotherapeutics presents data across Zoryve portfolio Arcutis Biotherapeutics…
Arcutis Biotherapeutics price target raised to $44 from $38 at Guggenheim
Guggenheim raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $44 from $38 and keeps a Buy rating on the shares. The firm has “... Arcutis Biotherapeutics price target raised to $44 from $38 at Guggenheim Guggenheim raised…
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Posted by Michael Walen on Oct 28th, 2026 View Our Latest Report on ARQT Shares of NASDAQ ARQT opened at $31.68 on Wednesday. Arcutis Biotherapeutics has a 52-week low of $19.30 and a 52-week high of $33.30. The firm has a 50 day moving…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com5
- defenseworld.net4
- markets.businessinsider.com4
- openpr.com2
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.